Referenzen / Literatur

Kinderklinik

Direktor:
Prof. Dr. med. Joachim Wölfle

 

1: Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results froma phase III trial.

Suttorp M, Schulze P, Glauche I, Göhring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT,  Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C. Leukemia. 2018 Jun 20. doi: 10.1038/s41375-018-0179-9.

2: Pharmacology and pharmacokinetics of imatinib in pediatric patients.

Suttorp M, Bornhäuser M, Metzler M, Millot F, Schleyer E. Expert Rev Clin Pharmacol. 2018 Mar;11(3):219-231. doi: 10.1080/17512433.2018.1398644.

3: Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.

 Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Blood. 2016 Jan 28;127(4):392-9. doi: 10.1182/blood-2015-06-648667.

4: Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.

Hijiya N, Millot F, Suttorp M. Pediatr Clin North Am. 2015 Feb;62(1):107-19. doi: 10.1016/j.pcl.2014.09.008. Review. PubMed PMID: 25435115.

5: Managing children with chronic myeloid leukaemia (CML): Recommendations for the management of CML in children and young people up to the age of 18 years.

De la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, Millot F; International BFM Group (iBFM) Study Group Chronic Myeloid Leukaemia Committee. Br J Haematol. 2014 Oct;167(1):33-47. doi: 10.1111/bjh.12977.